Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s flagship product candidates include Atrioventricular Interval Modulation (AVIM) therapy (BackBeat CNT) for the treatment of hypertension, the leading risk factor for death worldwide, and Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic coronary artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing, and organic development. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn and Twitter.
Company profile
Ticker
OBIO
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Health Sciences Acquisitions Corp 2
SEC CIK
Corporate docs
Subsidiaries
HSAC Olympus Merger Sub, Inc. ...
OBIO stock data
Latest filings (excl ownership)
S-3/A
Shelf registration (amended)
25 Apr 24
8-K
Other Events
29 Mar 24
S-8
Registration of securities for employees
27 Mar 24
S-3/A
Shelf registration (amended)
27 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Orchestra BioMed Corporate Presentation Q1 2024
6 Mar 24
8-K
Entry into a Material Definitive Agreement
27 Nov 23
8-K
Orchestra BioMed Corporate Presentation Q4 2023
14 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Orchestra BioMed Corporate Presentation Q4 2023
10 Oct 23
Latest ownership filings
4
David Pacitti
28 Mar 24
3
David Pacitti
28 Mar 24
5
Annual statement of changes in insider ownership
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
Medtronic plc
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
3
George Papandreou
29 Sep 23
3
Motus GI Holdings, Inc.
22 Sep 23
SC 13G
Motus GI Holdings, Inc.
22 Sep 23
SC 13G
PERCEPTIVE ADVISORS LLC
13 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.08 mm | 19.08 mm | 19.08 mm | 19.08 mm | 19.08 mm | 19.08 mm |
Cash burn (monthly) | (no burn) | 6.49 mm | 4.84 mm | 4.07 mm | 3.43 mm | 3.66 mm |
Cash used (since last report) | n/a | 44.71 mm | 33.33 mm | 28.03 mm | 23.60 mm | 25.19 mm |
Cash remaining | n/a | -25.63 mm | -14.26 mm | -8.95 mm | -4.52 mm | -6.11 mm |
Runway (months of cash) | n/a | -3.9 | -2.9 | -2.2 | -1.3 | -1.7 |
Institutional ownership, Q3 2023
64.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 44 |
Opened positions | 8 |
Closed positions | 5 |
Increased positions | 23 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 108.60 bn |
Total shares | 23.20 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
RTW Investments | 5.62 mm | $49.01 bn |
HSAC 2 | 5.11 mm | $0.00 |
MDT Medtronic | 5.00 mm | $0.00 |
Perceptive Advisors | 2.43 mm | $21.21 bn |
BLK Blackrock | 1.33 mm | $11.60 bn |
Vanguard | 1.25 mm | $10.87 bn |
T. Rowe Price | 624.62 k | $5.45 mm |
Geode Capital Management | 415.71 k | $3.63 bn |
Boxer Capital | 238.19 k | $2.08 bn |
STT State Street | 179.88 k | $1.57 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Mar 24 | Pacitti David | Common Stock, par value $0.0001 per share ("Common Stock") | Grant | Acquire A | No | No | 0 | 10,000 | 0.00 | 12,170 |
26 Mar 24 | Pacitti David | Stock Option Common Stock | Grant | Acquire A | No | No | 5 | 34,633 | 173.17 k | 34,633 |
13 Apr 23 | Medtronic | Common Stock | Grant | Acquire A | Yes | No | 0 | 869,493 | 0.00 | 5,868,916 |
News
Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
28 Mar 24
Orchestra BioMed Hldgs Q4 EPS $(0.37) Beats $(0.38) Estimate, Sales $262.00K Miss $990.00K Estimate
27 Mar 24
Orchestra BioMed Demonstrates Strength Of Cardiovascular Pipeline With Virtue SAB And AVIM Therapy Presentations At CRT 2024 Annual Meeting
13 Mar 24
Orchestra BioMed Announces Presentation Of Results From Clinical Study Demonstrating Hemodynamic Effects Of AVIM Therapy In Hypertensive Pacemaker Patients
6 Mar 24
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction In 24-Hour Ambulatory Systolic Blood Pressure In Hypertensive Pacemaker Patients Treated With AVIM Therapy For Over 3 Years
26 Feb 24
Press releases
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
27 Mar 24
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
13 Mar 24
Orchestra BioMed to Participate in Upcoming Investor Conferences
7 Mar 24
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
6 Mar 24